Enrichment-free Salmonella detection for food safety

项目总结/摘要 每年有超过100万人因食源性沙门氏菌感染而患病， 占美国报告的所有食源性疾病的11% 1。沙门氏菌是 食源性疾病住院（23，000例; 35%）和死亡（450 例，占28%。沙门氏菌对经济产生巨大影响，造成37亿美元的成本 在美国，每年的死亡率高达90%（330万美元），8%（294美元）是由于死亡造成的。 2000万人）和2%的非住院病例。的主要方式 沙门氏菌感染是通过食物，主要是生的或未煮熟的肉，生鸡蛋和未清洗的 蔬菜.这些疾病通常与受污染食物引起的疫情有关， 在制造或包装工厂没有检测到。目前的检测方法 沙门氏菌提供了缓慢的时间，以采取行动的结果，使其难以采取必要的步骤， 控制病原体Sample 6开发了一种新技术，基于专有的 Bioillumination PlatformTM，它利用一种新的合成工程方法， 噬菌体检测特定细菌种类存在的天然特异性。Sample6 DETECT/S系统含有工程噬菌体，可以鉴定沙门氏菌属。到 在感染靶细胞后，有效地诱导发光酶的产生， 启发沙门氏菌该信号可以用样品6光度计测量， 这是世界上第一个免富集病原体诊断系统。Sample 6以前 确定DETECT/S检测试剂盒适用于成品检测的可行性， 直接检测容易受到污染的食品上的沙门氏菌。对于这个直接- 第二期计划，我们建议完成我们的技术开发，以检测沙门氏菌 根据AOAC指南的规定，对其他食品进行验证。我们将扩大 检测包括400个属于临床相关血清型的沙门氏菌分离株，并完成 代表所有商业相关类别的20种食品基质的测定开发， 包括低水分食物。最后，我们将开发非复制噬菌体技术， BioIllumination平台，以进一步扩大我们在国内和国际市场的影响力。 化国际大

Project Summary/Abstract Each year over one million people become ill due to foodborne Salmonella infections, this accounts for a total of 11% of all foodborne illness reported in the United States1. Salmonella is the leading cause for foodborne illness hospitalizations (23,000 cases; 35%) and deaths (450 cases; 28%). Salmonella has an enormous impact on the economy, causing $3.7 billion in costs in the United States each year; 90% of this burden ($3.3 million) is due to deaths, 8% ($294 million) due to hospitalizations and 2% due to non-hospitalized cases. The primary mode of Salmonella infection is through food, mainly raw or undercooked meat, raw eggs and unwashed vegetables. These illnesses are often tied to outbreaks that result from contaminated food that was not detected at a manufacturing or packaging plant. Current detection methods for Salmonella provide slow time to actionable results, making it difficult to take necessary steps in controlling the pathogen. Sample6 has developed a new technology, based on the proprietary Bioillumination PlatformTM, which utilizes a novel synthetic engineering approach to leverage the natural specificity of bacteriophage to detect the presence of specific bacterial species. Sample6 DETECT/S system contains engineered bacteriophages, which can identify Salmonella spp. to induce production of luminescent enzymes, upon infection of the target cells, effectively illuminating Salmonella. This signal can be measured with the Sample6 Luminometer and instantiates the world's first enrichment-free pathogen diagnostic system. Sample6 has previously established feasibility that the DETECT/S assay can be adapted for finished product testing to detect Salmonella directly on food products that are prone to contamination. For this Direct-to- Phase II project, we propose to complete the development of our technology to detect Salmonella on additional foods to achieve validation as laid out in AOAC guidelines. We will expand the testing to include 400 Salmonella isolates belonging to clinically relevant serotypes, and complete assay development for 20 food matrices representing all commercially relevant categories, including low-moisture foods. Finally, we will develop non-replicating phage technology for our BioIllumination Platform to further increase our reach in the market, both domestically and internationally.